Search Results for "infusers"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for infusers. Results 381 to 390 of 405 total matches.
Tigecycline (Tygacil)
The Medical Letter on Drugs and Therapeutics • Sep 12, 2005 (Issue 1217)
of tigecycline
is 100 mg IV initially, followed by 50 mg IV every 12
hours. The drug should be infused over 30 ...
Tigecycline (Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure infections.
Abatacept (Orencia) for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006 (Issue 1229)
the first infusion. Arthritis
Rheum 2002; 46: 1470.
7. JM Kremer et al. Treatment of rheumatoid arthritis ...
Atacept (Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).
New Drugs for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Nov 12, 2012 (Issue 1403)
infusion reactions, infections, and development
of thyroid disorders and immune thrombocytopenic purpura ...
In recent years, several new drugs have been
approved by the FDA for use in multiple sclerosis
(MS), and many others are in the pipeline. Most
recently, teriflunomide (Aubagio – Genzyme) became
the second oral drug to be approved by the FDA for
treatment of relapsing forms of MS.
Lacosamide for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jun 29, 2009 (Issue 1315)
taking other drugs that prolong
the PR interval. Adverse events with IV infusion over
30 minutes were ...
The FDA has approved lacosamide (Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
and vomiting are most likely to occur after taking an oral
loading dose. Infusion-site reactions were reported ...
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults.
Romosozumab (Evenity) for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
myeloma, and bone metastases
from solid tumors.
9. Cost of one 5 mg/100 mL infusion bottle.
10 ...
The FDA has approved romosozumab-aqqg (Evenity –
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
Romosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) receptor
agonists abaloparatide (Tymlos) and...
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
is
recommended. Amisulpride should be infused over
1-2 minutes. The drug is subject to photodegradation ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Choice of Cephalosporin
The Medical Letter on Drugs and Therapeutics • Nov 30, 1990 (Issue 832)
include thrombophlebitis from intravenous (IV) infusions, pain at intramuscular (IM) injection sites ...
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Prevention and Treatment of Injury from Chemical Warfare Agents
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002 (Issue 1121)
at hourly intervals, if
necessary, or continuously at 500 mg/hour by IV infusion.
Diazepam − Early ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Nonopioid Drugs for Pain
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022 (Issue 1645)
neuralgia, and
intractable neuropathic pain such as poststroke
pain and spinal cord injury.40 IV infusions ...
Nonopioid drugs can be used in the treatment of
many nociceptive and neuropathic pain conditions.
For severe pain, especially severe chronic cancer
pain, use of opioids may be necessary. Noninvasive
nonpharmacologic treatments, including physical
and psychological therapies, have been shown to
improve pain and function in patients with some
common chronic pain conditions and are unlikely
to cause serious harms. A multimodal approach to
analgesic therapy can increase pain control while
reducing opioid use and adverse effects.